[go: up one dir, main page]

MX2018013729A - Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma. - Google Patents

Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.

Info

Publication number
MX2018013729A
MX2018013729A MX2018013729A MX2018013729A MX2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A
Authority
MX
Mexico
Prior art keywords
preparation
new
crystal form
dapagliflozin
crystalline form
Prior art date
Application number
MX2018013729A
Other languages
English (en)
Other versions
MX381433B (es
Inventor
Li Xiang
Yu Jun
He Lei;
Wang Jinjia
Du Zuyin
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of MX2018013729A publication Critical patent/MX2018013729A/es
Publication of MX381433B publication Critical patent/MX381433B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describe una forma cristalina nueva de dapagliflozina y un método de preparación y uso de la misma. En particular, se describe una forma cristalina E de 2-cloro-5- (ß-D-glucopiranosa-1-il)- 4'-etoxildifenilmetano y un método de preparación de la misma y una composición farmacéutica que contiene una cantidad terapéuticamente eficaz de la forma cristalina y al uso de la misma en el tratamiento de la diabetes tipo II.
MX2018013729A 2016-05-24 2017-05-22 Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma MX381433B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610347924 2016-05-24
PCT/CN2017/085295 WO2017202264A1 (zh) 2016-05-24 2017-05-22 达格列净新晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2018013729A true MX2018013729A (es) 2019-05-02
MX381433B MX381433B (es) 2025-03-12

Family

ID=60412111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013729A MX381433B (es) 2016-05-24 2017-05-22 Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma

Country Status (10)

Country Link
US (1) US10464915B2 (es)
EP (1) EP3466939B1 (es)
JP (1) JP7007300B2 (es)
KR (1) KR20190010578A (es)
CN (1) CN108699020B (es)
BR (1) BR112018071991A2 (es)
ES (1) ES2864153T3 (es)
MX (1) MX381433B (es)
TW (1) TWI747906B (es)
WO (1) WO2017202264A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110790735A (zh) * 2018-08-03 2020-02-14 北京海晶生物医药科技有限公司 一种达格列净新晶型n及其制备方法
CN111559997A (zh) * 2019-02-13 2020-08-21 罗欣药业(上海)有限公司 一种达格列净新晶型及其制备方法
CN111689936A (zh) * 2019-03-15 2020-09-22 罗欣药业(上海)有限公司 达格列净新晶型及其制备方法
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
RU2530494C2 (ru) * 2008-08-22 2014-10-10 Теракос, Инк. Способ получения ингибиторов sglt2
KR20140097258A (ko) * 2011-10-31 2014-08-06 시노팜 타이완 리미티드 Sglt2 억제제의 결정성 및 비-결정성 형태
US8952139B2 (en) * 2011-11-07 2015-02-10 Scinopharm Taiwan, Ltd Process for the preparation of β-C-aryl glucosides
EP2597090A1 (en) * 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
CN104829572B (zh) * 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法
CN104829573B (zh) * 2014-02-11 2018-09-07 江苏豪森药业集团有限公司 达格列净晶型及其制备方法
CN106543124A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 达格列净化合物

Also Published As

Publication number Publication date
US10464915B2 (en) 2019-11-05
EP3466939A4 (en) 2019-12-18
ES2864153T3 (es) 2021-10-13
MX381433B (es) 2025-03-12
EP3466939B1 (en) 2021-02-24
WO2017202264A1 (zh) 2017-11-30
TWI747906B (zh) 2021-12-01
TW201741327A (zh) 2017-12-01
CN108699020B (zh) 2021-10-15
KR20190010578A (ko) 2019-01-30
BR112018071991A2 (pt) 2019-02-12
CN108699020A (zh) 2018-10-23
EP3466939A1 (en) 2019-04-10
US20190218197A1 (en) 2019-07-18
JP2019516706A (ja) 2019-06-20
JP7007300B2 (ja) 2022-01-24

Similar Documents

Publication Publication Date Title
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CL2015003117A1 (es) Modificaciones en la estructura cristalina
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EP3895717C0 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CL2016002510A1 (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano [3,4-d][1,3] tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
GT201400111A (es) Triazolopiridinas sustituidas
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
EP3597208A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING ATPIF1 FOR THE TREATMENT OF DIABETES
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2018013729A (es) Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة